Pre-made Tildrakizumab benchmark antibody ( Whole mAb, anti-IL23A/IL23 therapeutic antibody, Anti-IL23P19/P19/SGRF Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-573
Pre-Made Tildrakizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tildrakizumab (trade name Ilumya (US)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Tildrakizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries|
|Conditions Approved||Plaque psoriasis|
|Conditions Active||Ankylosing spondylitis;Intervertebral disc degeneration;Non-radiographic axial spondyloarthritis;Psoriatic arthritis|
|Conditions Discontinued||Autoimmune disorders|